TECNOTREE
1.8.2024 15:30:28 CEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for BSS, OSS, AI, 5G, and cloud-native technologies, has partnered with MiFibra, a leading High-Speed Broadband Internet Service Provider in Perú, to update its Operations Support Systems and transform Fulfillment and Assurance processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801164212/en/
Tecnotree and MiFibra Collaborate to Revolutionize its Operations Support Systems (Graphic: Business Wire)
The strategic partnership will allow MiFibra to fully realize the potential of its Fiber to the Home (FTTH) network infrastructure, offering several benefits, such as the capability to automate feasibility, provisioning and maintenance of services, removing complexities and delays related to manual tasks, as well offering the capability to guarantee the quality of services (QoS) and the quality of the experience (QoE). The results of this partnership will allow MiFibra to accelerate the growth of its customer base, increase customer satisfaction and strengthen its position in the market.
It will also expose TMForum's open APIs for service qualification and activation, enabling seamless integration and compatibility with a variety of protocols and network elements. MiFibra will be able to fully optimize the capacity and usage of its network infrastructure, and, through efficient resources management, it will be able to achieve operational excellence.
Carlos Villegas, CEO of MiFibra, said: "The partnership between MiFibra and Tecnotree represents a transformative step towards comprehensive provisioning with greater and better information for commercial and technical customer management. Through this strategic alliance, MiFibra will be able to evolve its commercial and technical service platforms over time by incorporating digital self-management tools for the customer, a proactive communication portal for the customer, and tools for optimizing home equipment."
Padma Ravichander, CEO of Tecnotree Corporation, said, “We are delighted with this new partnership with MiFibra to embark on a transformative journey towards digitalization and operational efficiency, by revolutionizing their infrastructure and operational support systems. By leveraging our expertise in BSS, OSS, Artificial Intelligence and 5G technologies, Tecnotree will enable MiFibra to unlock its true potential and drive growth by provisioning services quicker and assurance of quality of its services. Through increased automation and streamlined processes, we will enable fast and agile interactions at scale, which will not only fuel MiFibra's customer base, but will also fortify their market position.”
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) & Operating Support System (OSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is No. 1 on the TM Forum Open API Conformance table with 59 Open APIs, a result of our pursuit of delivering excellence, and consistently providing differentiated experiences and services to the CSPs and DSPs. Our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
About MiFibra
MiFibra is a company founded by Peruvian executives with over 20 years of experience in the telecommunications sector. It currently has broadband fiber optic networks in the departments of Piura, Lambayeque, Trujillo, and Ancash, with coverage of more than 800,000 households and over 80,000 connected customers. It has been recognized by Ookla as the leading Fixed Internet operator in terms of speed in all the departments where it operates. Its mission is to bring world-class internet service to more and more Peruvians, and its vision is to become the number one operator wherever it operates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801164212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom